News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma to Present Clinical Data at the 2008 ACR/ARHP Annual Scientific Meeting

BOULDER, Colo.--(BUSINESS WIRE)--

Array BioPharma Inc. (Nasdaq: ARRY) today announced that clinical data will be presented on its p38 inhibitor, ARRY-797 and its MEK inhibitor, ARRY-162, at the 2008 ACR/ARHP Annual Scientific Meeting in San Francisco, Calif.

Title:     Potent Clinical Anti-inflammatory and Analgesic Activity of
            a Novel p38(alpha) Inhibitor ARRY-797 (Poster: 357)
Presenter: Ann E. Remmers, Director, Clinical Science - Pain and
            Supportive Care, Array BioPharma
Date:      Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.

Title:     ARRY-162, A Novel MEK Inhibitor: Results of a 14-Day Phase
            1a Study in Healthy Subjects and a 28-Day Phase 1b Study
            in Rheumatoid Arthritis patients (Poster: 358)
Presenter: Laura Carter, Research Investigator, Array BioPharma
Date:      Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.

Title:     ARRY-797, A Novel p38 MAP Kinase Inhibitor: Results of a
            14-Day Phase 1 Study (Poster: 359)
Presenter: Laura Carter, Research Investigator, Array BioPharma
Date:      Sunday, October 26, 2008, poster session, 9 - 11 a.m. P.T.

The posters will be available as PDFs after they are presented on Array's website: http://www.arraybiopharma.com/PatentsPublications/Default.asp? PBCategoryID=3 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.).

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.

Source: Array BioPharma Inc.